Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Ghofrani, HA; Morrell, NW; Hoeper, MM; Olschewski, H; Peacock, AJ; Barst, RJ; Shapiro, S; Golpon, H; Toshner, M; Grimminger, F; Pascoe, S.
Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.
AMER J RESPIR CRIT CARE MED. 2010; 182(9): 1171-1177.
Doi: 10.1164/rccm.201001-0123OC
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Olschewski Horst
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Rationale: Pulmonary arterial hypertension (PAH) is a progressive condition with a poor prognosis. Platelet-derived growth factor receptor (PDGFR) signaling plays an important role in its pathobiology. Objectives: To assess safety, tolerability, and efficacy of the PDGFR inhibitor imatinib in patients with PAN. Methods: Patients with PAN in functional classes II-IV were enrolled in a 24-week randomized, double-blind, placebo-controlled pilot study. Patients received imatinib (an inhibitor of PDGFR activity) 200 mg orally once daily (or placebo), which was increased to 400 mg if the initial dose was well tolerated. The primary endpoints were safety and change from baseline in the 6-minute-walk distance (6MWD). Secondary endpoints included hemodynamics and functional classification. Measurements and Main Results: Fifty-nine patients enrolled (imatinib [n = 28]; placebo [n = 31]); 42 completed the study. Dropouts were equally matched between the two groups. In the intention-to-treat (ITT) population there was no significant change in the 6MWD (mean +/- SD) in the imatinib versus placebo group (+ 22 +/- 63 versus -1.0 +/- 53 m). There was a significant decrease in pulmonary vascular resistance (imatinib -300 +/- 347 versus placebo -78 +/- 269 dynes . s . cm(-5), P < 0.01) and increase in cardiac output (imatinib +0.6 +/- 1.2 versus placebo -0.1 +/- 0.9 L/min, P = 0.02). Serious adverse events occurred in 11 imatinib recipients (39%) and 7 placebo recipients (23%). Three deaths occurred in each group. Post hoc subgroup analyses suggest that patients with greater hemodynamic impairment may respond better than patients with less impairment. Conclusions: These data from a Phase II study are consistent with imatinib being well tolerated in patients with PAH, and provide proof of concept for further studies evaluating its safety, tolerability, and efficacy in PAH. Clinical trial registered with www.clinicaltrials.gov (NCT00477269).
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Double-Blind Method -
- Exercise Test -
- Female -
- Humans -
- Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - physiopathology
- Intention to Treat Analysis -
- Lung - physiopathology
- Male -
- Middle Aged -
- Piperazines - pharmacology
- Protein Kinase Inhibitors - pharmacology
- Pyrimidines - pharmacology
- Receptors, Platelet-Derived Growth Factor - drug effects
- Respiratory Function Tests -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- pulmonary hypertension
- imatinib
- exercise
- hemodynamics